Pirfenidone.
Pirfenidone, an antifibrotic tissue growth antagonist, is in development for the potential treatment of fibrotic diseases including renal, liver and pulmonary fibrosis and for multiple sclerosis.
Lasky
Joseph
J
Tulane University Health Sciences Center, 1430 Tulane Avenue, SL-9, New Orleans, LA 70112, USA. jlasky@tulane.edu
D000818:Animals; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005355:Fibrosis / Q000188:drug therapy*; D006801:Humans; D011728:Pyridones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D011728:Pyridones; C093844:pirfenidone